trending Market Intelligence /marketintelligence/en/news-insights/trending/id_lfps7acexjvttkhuzxg2 content esgSubNav
In This List

Sun Pharmaceutical skin drug bags US FDA approval

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Sun Pharmaceutical skin drug bags US FDA approval

India's Sun Pharmaceutical Industries Ltd. secured the U.S. Food and Drug Administration's approval to market Ilumya as a treatment for moderate-to-severe plaque psoriasis.

Plaque psoriasis is a skin disease that causes red, painful and itchy patches with a silvery white buildup of dead skin cells or scale.

The company's regulatory filing was backed by the results of two phase 3 clinical trials that demonstrated the treatment was better at improving skin clearance than placebo.